SK278327B6 - 4-aryl-1,4-dihydropiridine-3,5-dicarboxylates and pharmaceutical agents containing them - Google Patents

4-aryl-1,4-dihydropiridine-3,5-dicarboxylates and pharmaceutical agents containing them Download PDF

Info

Publication number
SK278327B6
SK278327B6 SK4030-91A SK403091A SK278327B6 SK 278327 B6 SK278327 B6 SK 278327B6 SK 403091 A SK403091 A SK 403091A SK 278327 B6 SK278327 B6 SK 278327B6
Authority
SK
Slovakia
Prior art keywords
aryl
dimethyl
formula
carbon atoms
dihydropyridine
Prior art date
Application number
SK4030-91A
Other languages
English (en)
Slovak (sk)
Inventor
Alan D Borthwick
Original Assignee
Borthwick Alan D.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IT22383/84A external-priority patent/IT1175620B/it
Priority claimed from IT21460/85A external-priority patent/IT1187678B/it
Application filed by Borthwick Alan D. filed Critical Borthwick Alan D.
Publication of SK278327B6 publication Critical patent/SK278327B6/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C03—GLASS; MINERAL OR SLAG WOOL
    • C03B—MANUFACTURE, SHAPING, OR SUPPLEMENTARY PROCESSES
    • C03B2205/00—Fibre drawing or extruding details
    • C03B2205/44—Monotoring or regulating the preform feed rate

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SK4030-91A 1984-08-22 1991-12-23 4-aryl-1,4-dihydropiridine-3,5-dicarboxylates and pharmaceutical agents containing them SK278327B6 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT22383/84A IT1175620B (it) 1984-08-22 1984-08-22 Derivati piridinici
IT21460/85A IT1187678B (it) 1985-07-05 1985-07-05 Procedimento di preparazione di derivati eterociclici

Publications (1)

Publication Number Publication Date
SK278327B6 true SK278327B6 (en) 1996-11-06

Family

ID=26327905

Family Applications (1)

Application Number Title Priority Date Filing Date
SK4030-91A SK278327B6 (en) 1984-08-22 1991-12-23 4-aryl-1,4-dihydropiridine-3,5-dicarboxylates and pharmaceutical agents containing them

Country Status (33)

Country Link
US (2) US4801599A (es)
JP (2) JPS6193162A (es)
KR (1) KR920004482B1 (es)
AT (1) AT394042B (es)
AU (1) AU578724B2 (es)
BE (1) BE903103A (es)
BG (1) BG60409B2 (es)
CA (1) CA1268180A (es)
CH (1) CH666684A5 (es)
CS (1) CS403091A3 (es)
CY (1) CY1494A (es)
DE (1) DE3529997C2 (es)
DK (1) DK165949C (es)
ES (5) ES8703839A1 (es)
FI (1) FI81568C (es)
FR (1) FR2569402B1 (es)
GB (1) GB2164336B (es)
GR (1) GR852016B (es)
HK (1) HK52990A (es)
HU (1) HU196754B (es)
IE (1) IE58486B1 (es)
LU (2) LU86047A1 (es)
MX (1) MX159974A (es)
NL (2) NL193065C (es)
NO (2) NO167142C (es)
NZ (1) NZ212895A (es)
PH (1) PH22014A (es)
PT (1) PT81000B (es)
SA (1) SA91120277B1 (es)
SE (1) SE459920B (es)
SG (1) SG40889G (es)
SK (1) SK278327B6 (es)
ZW (1) ZW13185A1 (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ212895A (en) * 1984-08-22 1988-07-28 Glaxo Spa 1,4-dihydropyridine derivatives and pharmaceutical compositions
EP0226271B1 (en) * 1985-08-21 1990-11-22 GLAXO S.p.A. 1,4-dihydropyridine compounds and their preparation and pharmaceutical formulation
BE905297A (fr) * 1985-08-21 1987-02-20 Glaxo Spa Derives heterocycliques.
IT1204461B (it) * 1986-02-20 1989-03-01 Glaxo Spa Derivati eterociclici
IT1204462B (it) * 1986-02-20 1989-03-01 Glaxo Spa Derivati eterociclici
IT1204460B (it) * 1986-02-20 1989-03-01 Glaxo Spa Derivati eterociclici
IT1233370B (it) * 1988-11-21 1992-03-27 Glaxo Spa Procedimento di preparazione di derivati diidropipiridinici utili nel trattamento di disturbi cardiovascolari
DE69030982T2 (de) 1989-04-27 1997-11-13 Canon Kk Optisches Aufzeichnungsmedium und Verfahren zu seiner Herstellung
US5196529A (en) * 1990-10-09 1993-03-23 Merck & Co., Inc. 2-phenanthrenyl carbapenem intermediates
US5177202A (en) * 1990-10-09 1993-01-05 Merck & Co., Inc. 2-phenanthrenyl-carbapenems
US5132421A (en) * 1990-10-09 1992-07-21 Merck & Co., Inc. 2-naphthyl-carbapenem intermediates
US5132422A (en) * 1990-10-09 1992-07-21 Merck & Co., Inc. 2-naphthyl-carbapenem intermediates
US5144028A (en) * 1990-10-09 1992-09-01 Merck & Co., Inc. 2-(9-fluorenonyl)-carbapenem intermediates
US5356889A (en) * 1990-08-01 1994-10-18 Merck & Co., Inc. 2-(9-fluorenonyl)-carbapenem intermediates
US5208329A (en) * 1990-10-09 1993-05-04 Merck & Co., Inc. 2-biphenyl carbapenem intermediates
IT1244728B (it) * 1991-02-13 1994-08-08 Glaxo Spa Impiego medicamentoso di derivati diidropiridinici
TW483763B (en) * 1994-09-02 2002-04-21 Astra Ab Pharmaceutical composition comprising of ramipril and dihydropyridine compound
AU1042199A (en) * 1998-11-06 2000-05-29 Boehringer Ingelheim International Gmbh Antihypertensive medicaments containing lacidipine and telmisartan
AU2003250483A1 (en) 2002-08-19 2004-03-11 Pfizer Products Inc. Combination therapy for hyperproliferative diseases
CA2753318A1 (en) * 2003-05-30 2004-12-09 Ranbaxy Laboratories Limited Substituted pyrrole derivatives
US20050037063A1 (en) * 2003-07-21 2005-02-17 Bolton Anthony E. Combined therapies
EP1796653A2 (en) * 2004-07-26 2007-06-20 Actelion Pharmaceuticals Ltd. Treatment of pulmonary hypertension by inhaled iloprost with a microparticle formulation
EP1868577A4 (en) 2005-04-15 2009-12-09 Reddys Lab Inc Dr Lacidipine PARTICLE
US20070043088A1 (en) * 2005-08-16 2007-02-22 Eswaraiah Sajja Process for preparing lacidipine
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
EP2351569B1 (en) 2005-10-26 2012-08-22 Asahi Kasei Pharma Corporation Fasudil in combination therapies for the treatment of pulmonary arterial hypertension
ATE551059T1 (de) * 2005-10-26 2012-04-15 Asahi Kasei Pharma Corp Fasudil in kombination mit bosentan zur behandlung von pulmonaler arterieller hypertonie
US8026377B2 (en) * 2005-11-08 2011-09-27 Ranbaxy Laboratories, Limited Process for (3R, 5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid hemi calcium salt
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
US7919506B2 (en) 2006-03-10 2011-04-05 Pfizer Inc. Dibenzyl amine compounds and derivatives
WO2008020314A2 (en) * 2006-03-14 2008-02-21 Ranbaxy Laboratories Limited Statin stabilizing dosage formulations
TW200811101A (en) * 2006-07-14 2008-03-01 Ranbaxy Lab Ltd Polymorphic forms of an HMG-CoA reductase inhibitor and uses thereof
US20080089947A1 (en) * 2006-08-18 2008-04-17 Knox Clayton D Calcium Influx Inhibitors in the Treatment of Ischemia
JP5498168B2 (ja) 2006-12-01 2014-05-21 ブリストル−マイヤーズ スクイブ カンパニー アテローム性動脈硬化および循環器疾患の治療のためのｃｅｔｐ阻害剤としてのｎ−（（３−ベンジル）−２，２−（ビス−フェニル）−プロパン−１−アミン誘導体
WO2012037665A1 (en) 2010-09-24 2012-03-29 Oral Delivery Technology Ltd. Nitric oxide releasing amino acid ester for treatment of pulmonary hypertension and other respiratory conditions
EP2705839B1 (en) 2012-09-10 2018-02-21 Rivopharm SA Pharmaceutical composition comprising lacidipine and process of preparation
JP2016516804A (ja) 2013-04-17 2016-06-09 ファイザー・インク 心血管疾患を治療するためのｎ−ピペリジン−３−イルベンズアミド誘導体
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
JOP20210193A1 (ar) 2019-01-18 2023-01-30 Astrazeneca Ab مثبطات pcsk9 وطرق استخدامها

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3455945A (en) * 1967-06-07 1969-07-15 Smithkline Corp 4-(carboxy (and carbo-lower alkoxy)phenyl)-1,4-dihydropyridines
DE2228363A1 (de) * 1972-06-10 1974-01-03 Bayer Ag 1,4-dihydropyridine, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
GB1409865A (en) * 1973-02-13 1975-10-15 Science Union & Cie Dihydropyridines derivatives their preparation and pharmaceu tical compositions containing them
US4307103A (en) * 1978-09-08 1981-12-22 Fujisawa Pharmaceutical Co., Ltd. Dihydropyridine derivative, processes for preparation thereof and pharmaceutical composition comprising the same
DE3018259A1 (de) * 1980-05-13 1981-11-19 Bayer Ag, 5090 Leverkusen 1,4-dihydropyridine mit unterschiedlichen substituenten in 2- und 6-position, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln
NZ201395A (en) * 1981-07-30 1987-02-20 Bayer Ag Pharmaceutical compositions containing 1,4-dihydropyridines and certain of these dihydropyridines
DE3207982A1 (de) * 1982-03-05 1983-09-08 Bayer Ag, 5090 Leverkusen Neue 1,4-dihydropyridine, verfahren zu ihrer herstellung und ihrer verwendung in arzneimitteln
NZ212895A (en) * 1984-08-22 1988-07-28 Glaxo Spa 1,4-dihydropyridine derivatives and pharmaceutical compositions

Also Published As

Publication number Publication date
BE903103A (fr) 1986-02-24
ES8802497A1 (es) 1988-07-01
SE8503888D0 (sv) 1985-08-20
ES552049A0 (es) 1988-07-01
ES552048A0 (es) 1987-09-01
MX159974A (es) 1989-10-17
IE58486B1 (en) 1993-09-22
IE852054L (en) 1986-02-22
GR852016B (es) 1985-12-19
NZ212895A (en) 1988-07-28
US4801599A (en) 1989-01-31
AT394042B (de) 1992-01-27
NO853293L (no) 1986-02-24
JPS6479152A (en) 1989-03-24
ES552051A0 (es) 1987-09-01
CY1494A (en) 1990-02-16
SG40889G (en) 1989-12-22
JPH0550506B2 (es) 1993-07-29
ATA245485A (de) 1991-07-15
JPH0686430B2 (ja) 1994-11-02
ZW13185A1 (en) 1986-03-19
FI853206A0 (fi) 1985-08-21
DK165949B (da) 1993-02-15
KR870002073A (ko) 1987-03-28
GB2164336A (en) 1986-03-19
ES552050A0 (es) 1987-09-01
NO167142C (no) 1991-10-09
NO1999007I1 (no) 1999-04-23
SA91120277B1 (ar) 2006-05-15
GB2164336B (en) 1988-06-08
SE8503888L (sv) 1986-02-23
ES8707932A1 (es) 1987-09-01
CH666684A5 (de) 1988-08-15
DK165949C (da) 1993-07-05
AU578724B2 (en) 1988-11-03
GB8520924D0 (en) 1985-09-25
DE3529997C2 (de) 1996-01-18
PT81000B (pt) 1988-03-03
ES8707930A1 (es) 1987-09-01
DE3529997A1 (de) 1986-03-06
JPS6193162A (ja) 1986-05-12
FR2569402A1 (fr) 1986-02-28
ES546324A0 (es) 1987-03-01
FI853206L (fi) 1986-02-23
HU196754B (en) 1989-01-30
NL980037I1 (nl) 1999-02-01
NL193065B (nl) 1998-05-06
LU86047A1 (fr) 1986-02-28
PH22014A (en) 1988-05-02
US5011848A (en) 1991-04-30
FR2569402B1 (fr) 1989-09-22
NL8502296A (nl) 1986-03-17
DK378085A (da) 1986-02-23
NL980037I2 (nl) 1999-03-01
BG60409B2 (bg) 1995-02-28
PT81000A (en) 1985-09-01
LU88267I2 (es) 1994-02-03
HK52990A (en) 1990-07-20
DK378085D0 (da) 1985-08-20
FI81568C (fi) 1990-11-12
ES8703839A1 (es) 1987-03-01
NO167142B (no) 1991-07-01
CA1268180A (en) 1990-04-24
HUT40625A (en) 1987-01-28
CS403091A3 (en) 1992-06-17
ES8707931A1 (es) 1987-09-01
NL193065C (nl) 1998-09-08
SE459920B (sv) 1989-08-21
FI81568B (fi) 1990-07-31
AU4657685A (en) 1986-02-27
KR920004482B1 (ko) 1992-06-05

Similar Documents

Publication Publication Date Title
SK278327B6 (en) 4-aryl-1,4-dihydropiridine-3,5-dicarboxylates and pharmaceutical agents containing them
JPH05271078A (ja) ジヒドロピリジン類
US5670525A (en) Substituted 4-phenyl-6-amino-nicotinic acid compounds useful in the treatment of CNS disorders
US4946851A (en) 1.4-dihydropyridines
US4806533A (en) 1,4-Dihydro pyridine 3,5 dicarboxylic acid derivatives and compositions
US4654353A (en) Antihypertensive 2-hydroxyalkoxyalkyl dihydropyridines
JP2007084567A (ja) フエニル−置換１，４−ジヒドロピリジン類
US4839348A (en) 1,4-dihydropyridines
US4898865A (en) [4-(6-Oxo-1,4,5,6-tetrahydro-3-pyridazinyl) anilino hexyl 1,4-dihydro-2,6 Di methyl 5 nitro 4 aryl pyridine 3-carboxylates
US5051432A (en) Heterocyclic 1,4 dihydropyridine derivatives
NL192385C (nl) 6-alkyl-4-fenyl-1,4-dihydro-3,5-pyridinecarbonzuuresters, werkwijze voor de bereiding daarvan en farmaceutische preparaten die deze esters bevatten.
EP0242950B1 (en) Dihydropyridines, process for their preparation and their use as therapeutics
RU1816282C (ru) Способ получени производных 2-аминоалкилтиометил-1,4-дигидропиридина или их энантиомеров
US4957930A (en) Dihydropyridine derivatives
EP0226271B1 (en) 1,4-dihydropyridine compounds and their preparation and pharmaceutical formulation